# Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Study · id `cardio:ct-nct02471404` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02471404](<https://clinicaltrials.gov/study/NCT02471404>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02471404

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 939 participants.

## Technical summary

Registry record NCT02471404. Randomized; triple masking; primary purpose treatment. Start 2015-09-21 (actual); primary completion 2017-03-13 (actual). Results posted on 2019-03-26.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 939 participants (enrolled count; ClinicalTrials.gov record NCT02471404, source copy `cardio:ctgov-nct02471404-2019-03-26`, retrieved 2026-10-26)
- Started: 2015-09-21 (actual) (ClinicalTrials.gov record NCT02471404, source copy `cardio:ctgov-nct02471404-2019-03-26`, retrieved 2026-10-26)
- Primary completion: 2017-03-13 (actual) (ClinicalTrials.gov record NCT02471404, source copy `cardio:ctgov-nct02471404-2019-03-26`, retrieved 2026-10-26)
- Completion: 2017-03-13 (actual) (ClinicalTrials.gov record NCT02471404, source copy `cardio:ctgov-nct02471404-2019-03-26`, retrieved 2026-10-26)
- Results first posted: 2019-03-26 (ClinicalTrials.gov record NCT02471404, source copy `cardio:ctgov-nct02471404-2019-03-26`, retrieved 2026-10-26)
- Countries: Czechia; Germany; Hungary; Poland; Slovakia (ClinicalTrials.gov record NCT02471404, source copy `cardio:ctgov-nct02471404-2019-03-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02471404-2019-03-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea
- Condition: Type 2 Diabetes Mellitus
- Condition: Inadequate Glycaemic Control
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Saxagliptin
- Intervention (Drug): Glimepiride
- Intervention (Drug): Placebo for dapagliflozin
- Intervention (Drug): Placebo for saxagliptin
- Intervention (Drug): Placebo for glimepiride
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes (`cardio:pubmed-29947099`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f08efcc5f28f170dd8f510cf562231bc5923e9750e769c473cfef8fd4e1e91ad
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
